Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EntreMed commences MKC-1 trial in leukemia
The study will be conducted at the University of Texas MD Anderson Cancer Center. MKC-1 is also being evaluated currently in a phase II clinical study in patients
The study will be conducted at the University of Texas MD Anderson Cancer Center. MKC-1 is also being evaluated currently in a phase II clinical study in patients
If successful this trial could represent a breakthrough in influenza vaccines. Sanofi Pasteur will attempt to diversify the influenza vaccine market by basing the vaccines on cell culture
RTP-801 is involved in the development of blood vessels which accelerate the progression of age-related macular degeneration (AMD). Financial terms of the agreement were not announced and the
This award combined with an earlier phase 1 small business innovation research (SBIR) grant award brings total program funding to approximately $2.3 million. The grants will be used
The treatment is developed for patients who are tolerant to opioid therapy for their underlying persistent cancer pain. Fentora is the first and only buccal tablet approved for
The labeling now states that the condition, reversible posterior leukoencephalopathy syndrome (RPLS), could be a potential side-effect after taking Avastin. The rare brain disorder is bleeding syndrome that
Azixa is being developed to treat brain cancer. Azixa represents the first confirmed clinical proof of concept for this new technology, which is the basis for the Epicept's
The vaccine is co-developed with Novartis Vaccines and Diagnostics and has been manufactured to prevent a number of childhood diseases. Following the awarding of licensure by the Korea
The FDA has determined that Perrigo's famotidine tablets, is bioequivalent to Maximum Strength Pepcid AC tablets distributed by Johnson & Johnson and Merck & Co. Famotidine is indicated
Merck made the decision to discontinue development of MK-0354, an investigational niacin receptor, following completion of a phase II clinical trial that evaluated patients with dyslipidemia. Arena commented